δ opioid affinity and selectivity of 4-hydroxy-3-methoxyindolomorphinan analogues related to naltrindole

被引:36
作者
Coop, A
Rothman, RB
Dersch, C
Partilla, J
Porreca, F
Davis, P
Jacobson, AE
Rice, KC
机构
[1] NIDDK, Med Chem Lab, NIH, Bethesda, MD 20892 USA
[2] NIDA, Addict Res Ctr, Clin Psychopharmacol Sect, Baltimore, MD 21224 USA
[3] Univ Arizona, Hlth Sci Ctr, Dept Pharmacol, Tucson, AZ 85724 USA
关键词
D O I
10.1021/jm9807003
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
To investigate the effect of the introduction of a 4-phenolic substituent on the delta opioid affinity and selectivity of the indolomorphinans, a range of 4-phenolic analogues of naltrindole were prepared and evaluated in in vitro assays. Although the majority of the ligands displayed poor affinity for all three opioid receptors (mu, kappa, delta), 17-cyclopropylmethyl-6,7-didehydro-4-hydroxy-3-methoxy-6,7:2',3'-indolomorphinan (13) was an exception, displaying excellent delta binding selectivity (delta K-i = 7 nM, mu/delta = 1900, mu/kappa = 1130). GTP-gamma-S functional assays showed 13 to be a selective delta antagonist, albeit with lower potency than naltrindole. Although the reason for the unique profile of 13 could not be determined, these results validate our approach of introducing groups into the indolomorphinans that are known to reduce mu activity, to obtain increased delta selectivity.
引用
收藏
页码:1673 / 1679
页数:7
相关论文
共 54 条
[51]   [D-ALA2]DELTORPHIN-I BINDING AND PHARMACOLOGICAL EVIDENCE FOR A SPECIAL SUBTYPE OF DELTA-OPIOID RECEPTOR ON HUMAN AND INVERTEBRATE IMMUNE CELLS [J].
STEFANO, GB ;
MELCHIORRI, P ;
NEGRI, L ;
HUGHES, TK ;
SCHARRER, B .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (19) :9316-9320
[52]   AGONIST AND ANTAGONIST ACTIVITIES OF LIGANDS DERIVED FROM NALTREXONE AND OXYMORPHONE [J].
TAKEMORI, AE ;
SULTANA, M ;
NAGASE, H ;
PORTOGHESE, PS .
LIFE SCIENCES, 1992, 50 (20) :1491-1495
[53]   SELECTIVE NATREXONE-DERIVED OPIOID RECEPTOR ANTAGONISTS [J].
TAKEMORI, AE ;
PORTOGHESE, PS .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1992, 32 :239-269
[54]  
Tseng LF, 1997, J PHARMACOL EXP THER, V280, P600